<DOC>
	<DOCNO>NCT00348283</DOCNO>
	<brief_summary>The goal study test whether adalimumab induce mucosal heal subject moderate severe ileocolonic Crohn 's Disease .</brief_summary>
	<brief_title>Effects Adalimumab Mucosal Healing Subjects With Crohn 's Disease Involving Colon</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Crohn 's Disease great 4 month . A diagnosis ileocolonic Crohn 's Disease confirm endoscopy radiologic evaluation within 3 year Baseline . For subject operation ileocolonic region intestine document diagnosis ileocolonic disease , postoperative recurrence disease must document . Endoscopic documentation ulceration Screening correspond score 2 3 least one five segment colon Ulcerated Surface subscore Simple Endoscopic Score Crohn 's Disease ( SESCD ) . Crohn 's Disease Activity Index ( CDAI ) score &gt; = 220 &lt; = 450 . Males females &gt; = 18 &lt; = 75 year age Baseline visit . Adequate cardiac , renal hepatic function determine Principal Investigator demonstrate Screening laboratory evaluation , questionnaire , physical examination result indicate abnormal clinical condition would place subject undue risk thus preclude subject participation study . Subjects must able selfinject study medication designee healthcare professional inject study medication . Subjects must agree undergo 4 endoscopy . History cancer lymphoproliferative disease successfully completely treat cutaneous squamous cell basal cell carcinoma carcinoma − insitu cervix . History listeria , human immunodeficiency virus ( HIV ) , hepatitis B , immunodeficiency syndrome , central nervous system ( CNS ) demyelinate disease , untreated tuberculosis ( TB ) . Subject current diagnosis ulcerative colitis indeterminate colitis determine Investigator Abbott Medical Monitor . Subject surgical bowel resection within past 6 month plan resection time point enrol study . Subject ostomy ileoanal pouch . ( Subjects previous ileorectal anastomosis exclude ) . Subject receive investigational biological agent past 3 month 5 halflives prior Baseline ( whichever longer ) . Subjects poorly control medical condition condition , opinion Investigator sponsor , would put subject risk participation protocol . Subject previously use infliximab antiTNF ( anti tumor necrosis factor ) , even investigational , within 8 week Baseline . Subject previously use infliximab antiTNF agent clinically respond . Previous treatment adalimumab previous participation adalimumab clinical study . Subjects prednisone &gt; 40 mg/day ( equivalent ) . Subjects budesonide &gt; 9 mg/day . Subjects prior exposure Tysabri® ( natalizumab ) . Subjects previous history dysplasia gastrointestinal tract , find dysplasia biopsy perform Screening endoscopy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>